Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs. Our mature and unique understanding of the science is foundational to …

Agios was founded in 2008 to unlock a new field of discovery in cellular metabolism. This singular focus on metabolic disease has taken us from the development of precision therapies in oncology to …

Nov 19, 2025 · Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Agios is committed to creating value for shareholders by creating value for patients and healthcare providers. Find out how in our latest press releases and SEC filings, upcoming events and other …

As we create the future of Agios together, we are building on our core values and pioneering leadership in cellular metabolism to advance our work on behalf of people with rare diseases.

At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments …

Jan 13, 2025 · In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website …

Agios offers the myAgios ® patient support services program as a single point of engagement for eligible patients, including access support, prescription fulfillment, financial assistance, disease education …

Read More PDF Version Jul 31, 2025 Agios Reports Second Quarter 2025 Financial Results and Provides Business Update Read More PDF Version

At Agios, we are studying how PK activation could potentially benefit people with SCD. PK activation modulates 2,3-diphosphoglycerate (2,3-DPG) levels in RBCs which reduces hemoglobin S …